Drugs / IBI3033
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07549984 | Apr 2026 → Feb 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07456839 | Mar → Sep 2026 overdue | — | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07311226 | Dec 2025 → Jun 2026 overdue | — | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07311226 ↗ |
| Route | Intravenous | “Participants in IBI3033 group will receive a signle dose of IBI3033 at the protocol specified dose SC/IV.” NCT07311226 ↗ |
| Route | Subcutaneous | “Participants in IBI3033 group will receive a signle dose of IBI3033 at the protocol specified dose SC/IV.” NCT07311226 ↗ |